Dr. Moon J. Noh has been with Kolon TissueGene for over 16 years. Prior to his role here, Dr. Noh was the Director of the Biotechnology Lab at Kolon Central Research Park. Dr. Noh holds a Ph.D. and M.S. from the Korea Advanced Institute of Science and Technology in Molecular Biology.

Dr. Seng-Ho Jeon holds a Ph.D. in Pharmaceutical Sciences from Yonsei University, an MBA from Aalto University School of Business, a Master’s degree in Pharmaceutical Sciences from Seoul National University, and a Bachelor’s degree in Pharmacy from Seoul National University.

He served as CEO and President of Daewoong Pharmaceutical from 2018 to 2024, where he led the company’s growth and global expansion. He also held concurrent leadership roles, including CEO of Affycell Therapeutics (2020 to April 2024) and CEO of Daewoong Investment (2023 to April 2024). In addition, he has been serving as a board member of Korea Science & Technology Holdings since 2023, and as an advisor and board member at the Future Medicine Research Foundation since 2021.

Soon-Wook Kweon joined Kolon TissueGene, Inc. in May 2017 as Chief Financial Officer and currently serves as the head of the Korea branch. Before he joined Kolon TissueGene, he served as the Vice President of the Management & Finance Division in Kolon Corporation. He received his Bachelor of Arts in Economics at Korea University in Korea.

Jung In Kim joined Kolon TissueGene, Inc. in December, 2021 as the Chief Financial Officer. Before she joined Kolon TissueGene, she served as a director of the Management and Finance division in Kolon Corporation. She received his Bachelor of Arts in Mathematics at Kookmin University in Korea and acquired her CPA license from Korea Institute of Certified Public Accountant.

Gun-Young Park joined Kolon TissueGene, Inc. in 2022 and currently serves as Chief Operating Officer. Prior to joining Kolon TissueGene, he worked in the Secretariat of the One&Only Committee at Kolon Corporation since 2018. From 2007 to 2018, he served in the Strategic Planning Team at Kolon Life Science, Inc. He received his Bachelor of Arts in Economics and Business from Ajou University in Korea in 2007.

Thierry Uh joined Kolon TissueGene, Inc. in June 2025 as Chief Commercial Officer. Prior to joining Kolon TissueGene, he served as President and CEO of Daewoong Innovation Holdings, Inc., where he led Daewoong’s global open-collaboration initiatives. His previous roles include serving as a Partner at FreeMind Investment and as a Board Director and Head of Business Development at AffyXell Therapeutics.

He holds a Doctor of Veterinary Medicine from Chungnam National University and pursued advanced studies in Pain and Neurophysiology at the Seoul National University School of Veterinary Medicine.

Diana M. Halim joined Kolon TissueGene, Inc. in January 2020 as Senior Director of Regulatory Affairs and shortly thereafter became Vice President of Clinical and Regulatory Affairs. She previously served as the Director of Regulatory Affairs at RRD International, LLC, Sucampo Pharmaceuticals, Inc., and AnGes, Inc. She received her B.A. degree in English/Biology from George Washington University, Washington, DC and her M.S. degree in Biotechnology from Johns Hopkins University, Baltimore, MD.